Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|NSC-CRAd-Survivin-pk7||NSC-CRAd-Survivin-pk7 is a virotherapy comprised of an oncolytic virus driven by the survivin promoter and delivered via allogeneic neural stem cells, potentially resulting in reduced tumor burden and a cytotoxic effect in tumor cells expressing survivin (PMID: 30719498).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||ovarian cancer||not applicable||NSC-CRAd-Survivin-pk7||Preclinical - Cell line xenograft||Actionable||In a preclinical study, NSC-CRAd-Survivin-pk7 therapy resulted in decreased growth of ovarian cancer cells in culture and reduced tumor burden in cell line xenograft models (PMID: 30719498).||30719498|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT03072134||Phase I||NSC-CRAd-Survivin-pk7||Neural Stem Cell Based Virotherapy of Newly Diagnosed Malignant Glioma||Completed|